Peter Borchmann

13PUBLICATIONS
91CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 23, 2026
Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA.

|Sep 17, 2026
Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL.

|Aug 21, 2026
BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|May 26, 2025
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.

Louise Marie Cremer, Ullrich Bethe, Peter Borchmann

Pageof 3

Frequent Collaborators

6 joint publications

Paul Jan Bröckelmann

5 joint publications

Michael Fuchs

5 joint publications

Bastian von Tresckow

3 joint publications

Janina Jablonski